BRIEF—Kymera collaborates with GSK

UK biotech firm Kymera Therapeutics has entered into a two-year discovery collaboration agreement with GlaxoSmithKline, a science-led global healthcare company that is leveraging innovations in small molecule-based targeted protein degradation and encoded library technologies.

Under the terms of the agreement, GSK and Kymera will work together on a limited number of protein degradation targets of mutual interest to discover novel drug candidates.

The companies also agree to collaborate to discover novel E3 ligases – the enzymes that bind and target disease-causing proteins marking them for degradation.

The agreement supports ongoing collaboration between company scientists, with each company also having a right to use certain insights gained in the collaboration for its own programs.

"E3 ligase discovery is part of Kymera's larger strategy to expand the current E3 ligase toolbox, advance the chemistry and the biology of E3 ligases and provide a next-generation solution to developing protein degrading therapeutics," said Nello Mainolfi, co-founder and chief technology officer, Kymera Therapeutics.